Effects of PEA-LUT on Frontal Lobe Functions and GABAergic Transmission in Long-Covid Patients

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 16, 2021

Primary Completion Date

February 15, 2022

Study Completion Date

March 15, 2022

Conditions

FatigueCognitive DeficitCOVID-19Neurophysiologic Abnormality

Interventions

DIETARY_SUPPLEMENT

palmitoylethanolamide co-ultramicronized with antioxidant flavonoid luteolin (PEA-LUT)

assumption of the product at dosage of 700/70 mg 2 time/day for 8 weeks

DIETARY_SUPPLEMENT

Placebo

assumption of a placebo product 2 time/day for 8 weeks

Trial Locations (1)

Hospital of Vipiteno-Sterzing, Sterzing

All Listed Sponsors

collaborator

I.R.C.C.S. Fondazione Santa Lucia

OTHER

lead

Department of Neurorehabilitation, Hospital of Vipiteno-Sterzing (BZ) Italy

NETWORK

NCT05311852 - Effects of PEA-LUT on Frontal Lobe Functions and GABAergic Transmission in Long-Covid Patients | Biotech Hunter | Biotech Hunter